Drugs and their molecular targets: An updated overview

Fundamental and Clinical Pharmacology

Volumn 22, Issue 1, 2008, Pages 1-18

  Landry, Yves ^a   Gies, Jean Pierre ^a  

^a CNRS   (France)

Author keywords

Drug target; Druggability; New drug; Orphan receptor; Selectivity

Indexed keywords

ALPHA GALACTOSIDASE; AMINOPEPTIDASE; BECAPLERMIN; BONE MORPHOGENETIC PROTEIN 2; CELL NUCLEUS RECEPTOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; IMIDAZOLINE DERIVATIVE; INTEGRIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LARONIDASE; LEVO IDURONIDASE; MONOCLONAL ANTIBODY; PARACETAMOL; PLATELET DERIVED GROWTH FACTOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TASONERMIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

BINDING AFFINITY; CHANNEL GATING; DRUG BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; ENZYME REPLACEMENT; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW;

DRUG DESIGN; ENZYMES; HUMANS; ION CHANNELS; LIGANDS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 38649120829     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00548.x     Document Type: Review

References (79)

1. Golden J.B. Prioritizing the human genome knowledge management for drug discovery. Curr. Opin. Drug Discov. Dev 2003) 6 10 16.
2. Zheng C., Han L., Yap C.W., Xie B., Chen Y. Progress and problems in the exploration of therapeutic targets. Drug Discov. Today (2006) 11 412 420.
3. Imming P., Sinning C., Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Rev. Drug Discov. (2006) 5 821 834.
4. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there? Nature Rev. Drug Discov. (2006) 5 993 996.
5. Landry Y., Gies J.P. Pharmacologie, des cibles vers l'indication thérapeutique, Dunod, Paris, 2003.
6. Daeffler L, Landry Y. Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential. Fundam. Clin. Pharmacol. (2000) 14 73 87.
7. Bond R.A., Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. (2006) 27 92 96.
8. Hawes M.L., Kennedy W., O'callaghan M.W., Thurberg B.L. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Mol. Genet. Metab. (2007) 91 343 351.
9. Roussidis A.E., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. (2007) 14 735 743.
10. Zavrski I., Kleeberg L., Kaiser M. et al. Proteasome as an emerging therapeutic target in cancer. Curr. Pharm. Des. (2007) 13 471 485.
11. Dubey S., Satyanarayana Y.D., Lavania H. Development of integrase inhibitors for treatment of AIDS: an overview. Eur. J. Med. Chem. (2007) 42 1159 1168.
12. Singh N., Cheve G., Avery M.A., McCurdy C.R. Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme. Curr. Pharm. Des. (2007) 13 1161 1177.
13. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature (2007) 446 749 757.
14. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2 48 58.
15. Lipecka J., Norez C., Bensalem N. et al. Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J. Pharmacol. Exp. Ther. (2006) 317 500 505.
16. Verkman A.S., Lukacs G.L., Galietta L.J. CFTR chloride channel drug discovery - inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr. Pharm. Des. (2006) 12 2235 2247.
17. Pedemonte N, Boido D., Moran O. et al. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol. Pharmacol. (2007) 72 197 207.
18. Camerino D.C., Tricarico D., Desaphy J.-F. Ion channel pharmacology. Neurotherapeutics (2007) 4 184 198.
19. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review. Int. J. Clin. Pharmacol. Ther. (2006) 44 478 483.
20. Lory P., Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin. Ther. Targets (2007) 11 717 722.
21. Judge S.I., Bever C.T. Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol. Ther. (2006) 111 224 259.
22. + channel. J. Biol. Chem. (2004) 279 21774 21778.
23. Ledoux J., Werner M.E., Brayden J.E., Nelson M.T. Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) (2006) 21 69 78.
24. Ruzyllo W., Tendera M., Ford I., Fox K.M. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs (2007) 67 393 405.
25. Pifferi S., Boccaccio A., Menini A. Cyclic nucleotide-gated ion channels in sensory transduction. FEBS Lett. (2006) 580 2853 2859.
26. Nilius B., Owsianik G., Voets T., Peters J.A. Transient receptor potential cation channels in disease. Physiol. Rev. (2007) 87 165 217.
27. Okuhara D.Y., Hsia A.Y., Xie M. Transient receptor potential channels as drug targets. Expert Opin. Ther. Targets (2007) 11 391 401.
28. Bodding M. TRP proteins and cancer. Cell Signal. (2007) 19 617 624.
29. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. (2007) 87 659 797.
30. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. (2007) 7 39 47.
31. O'Neill M.J., Witkin J.M. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr. Drug Targets (2007) 8 603 620.
32. Romanelli M.N., Gratteri P., Guandalini L., Martini E., Bonaccini C., Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Chem. Med. Chem. (2007) 2 746 767.
33. Betz H., Laube B. Glycine receptors: recent insights into their structural organization and functional diversity. J. Neurochem. (2006) 97 1600 1610.
34. Vesely D.L. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin. Exp. Pharmacol. Physiol. (2006) 33 169 176.
35. Akhurst R.J. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs (2006) 7 513 521.
36. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets (2006) 6 107 121.
37. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. (2006) 71 713 721.
38. Garcia V.E., Chuluyan H.E. SLAM and CD31: signaling molecules involved in cytokine secretion during the development of innate and adaptive immune responses. Cytokine Growth Factor Rev. (2007) 18 85 96.
39. Wagner G., Laufer S. Small molecular anti-cytokine agents. Med. Res. Rev. (2006) 26 1 62.
40. Le G.T., Abbenante G. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. Curr. Med. Chem. (2005) 12 2963 2977.
41. Lee M.R., Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. (2005) 12 2979 2994.
42. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann. Med. (2006) 38 200 211.
43. Dean E.J., Ranson M., Blackhall F., Holt S.V., Dive C. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat. Rev. (2007) 33 203 212.
44. Hamdy N.A. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr. Opin. Investig. Drugs (2007) 8 299 303.
45. Stupp R., Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. (2007) 25 1637 1638.
46. Haddad E.B., Landry Y., Gies J.P. Sialic acid residues as catalysts for M2-muscarinic agonist receptor interactions. Mol. Pharmacol. (1990) 37 682 688.
47. Landry Y., Niederhoffer N., Sick E., Gies J.-P. Heptahelical and other G-protein-coupled receptors (GPCRs) signalling. Curr. Med. Chem. (2006) 13 51 63.
48. Chung S., Civelli O. Orphan neuropeptides. Novel neuropeptides modulating sleep or feeding. Neuropeptides (2006) 40 233 243.
49. Levoye A., Dam J, Ayoub M.A., Guillaume J.L., Jockers R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers EMBO Rep. (2006) 7 1094 1098.
50. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. (2001) 11 130 135.
51. Isenberg J.S., Romeo M.J., Abu-Asab M. et al. Increasing survival of ischemic tissue by targeting CD47. Circ. Res. (2007) 100 712 720.
52. Kaczorowski D.J., Billiar T.R. Targeting CD47: NO limit on therapeutic potential. Circ. Res. (2007) 100 602 603.
53. Landry Y., Gies J.P. Heterotrimeric G-proteins control diverse pathways of transmembrane signaling, a base for drug discovery. Mini. Rev. Med. Chem. (2002) 2 361 372.
54. Chahdi A., Daeffler L., Gies J.P., Landry Y. Drugs interacting with G protein alpha subunits: selectivity and perspectives, Fundam. Clin. Pharmacol. (1998) 12 121 132.
55. Iwatsubo K., Okumura S., Ishikawa Y. Drug therapy aimed at adenylate cyclase to regulate cyclic nucleotide signaling Endocr. Metab. Immune Disord. Drug Targets (2006) 6 239 247.
56. Ke H., Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr. Top. Med. Chem. (2007) 7 391 403.
57. Wetzker R., Rommel C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr. Pharm. Des. (2004) 10 15 22.
58. McMullen J.R., Jay P.Y. PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle (2007) 6 910 913.
59. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 23 3151 3171.
60. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Hood J., Soll R. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem. Soc. Trans. (2007) 35 204 206.
61. Bronner C., Chataigneau T., Schini-Kerth V.B., Landry Y. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. Curr. Med. Chem. (2007) 14 2629 2641.
62. Frojdo S., Cozzone D., Vidal H., Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. (2007) 406 511 518.
63. Musa M.A., Khan M.O., Cooperwood J.S. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr. Med. Chem. (2007) 14 1249 1261.
64. Rosen C.J. The rosiglitazone story. Lessons from an FDA advisory committee meeting. N. Engl. J. Med. (2007) 357 844 846.
65. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta (2007) 1171 1065 1081.
66. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam. Horm. (2007) 75 1 32.
67. Jakel H., Fruchart-Najib J., Fruchart J.C. Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. Drug News Perspect. (2006) 19 91 97.
68. Cao G., Bales K.R., DeMattos R.B., Paul S.M. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. (2007) 4 179 184.
69. Rizzo G., Renga B., Mencarelli A., Pellicciari R., Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2005) 5 289 303.
70. Pellicciari R., Sato H., Gioiello A. et al. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. (2007) 50 4265 4268.
71. Stein R.A., McDonnell D.P. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr. Relat. Cancer 2006) 13 (Suppl 1) 25 32.
72. Albiston A.L., McDowall S.G., Matsacos D. et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. (2001) 276 48623 48626.
73. Albiston A.L., Mustafa T., McDowall S.G., Mendelsohn F.A., Lee J., Chai S.Y. AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol. Metab. (2003) 14 72 77.
74. Ruiz-Ortega M., Esteban V, Egido J. The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc. Med. (2007) 17 19 25.
75. Duman R.S., Newton S.S. Epigenetic marking and neuronal plasticity. Biol. Psychiatry (2007) 62 1 3.
76. Bronner C., Achour M., Arima Y., Chataigneau T., Saya H., Schini-Kerth V.B. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol. Ther. (2007) 115 419 434.
77. Smith L.T., Otterson G.A., Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. (2007) in press
78. Field M.J., Cox P.J., Stott E. et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U.S.A. (2006) 103 17537 42.
79. Dooley D.J., Taylor C.P., Donevan S., Feltner D. Ca2 + channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. (2007) 28 75 82.